LONDON/ABIDJAN – West African nations are facing a critical juncture in their decades-long battle against Lassa fever, with the potential for a licensed vaccine within the next ten years. However, experts warn that proactive planning is essential to ensure a swift and effective rollout, addressing key questions of vaccine prioritization, delivery mechanisms, and sustainable financing.
Lassa fever, a viral hemorrhagic illness transmitted by rodents, remains a significant public health challenge across West Africa. The disease often presents with symptoms similar to other fevers, leading to underdiagnosis and delayed treatment. This diagnostic difficulty, coupled with limited access to healthcare in rural areas, contributes to preventable deaths and substantial economic losses. Estimates suggest the virus causes roughly $160 million in losses annually across West Africa, primarily due to reduced productivity.
Recognizing the urgency, the West African Health Organization (WAHO) and health ministers from affected countries established the Lassa fever Coalition in 2024. Supported by the Coalition for Epidemic Preparedness Innovations (CEPI), the coalition aims to strengthen vaccine trial networks, facilitate regional data sharing, and develop the necessary regulatory frameworks for vaccine introduction and widespread use. This builds upon existing improvements in surveillance, research, and outbreak response undertaken by national public health institutes and research organizations.
The need for preparedness stems from lessons learned from previous vaccine rollouts. The example of the human papillomavirus (HPV) vaccine highlights the potential for delays and inefficiencies. Initially recommended as a three-dose series, research later demonstrated that a single dose provided comparable efficacy. The adoption of the one-dose schedule, though ultimately beneficial, was delayed by 16 years after initial regulatory approval. A study suggests that implementing the one-dose schedule just five years earlier could have prevented an estimated 150,000 lives.
To avoid similar setbacks with a Lassa fever vaccine, policymakers must proactively address critical questions before regulatory approval. These include establishing clear criteria for prioritizing vaccination, particularly for vulnerable populations such as healthcare workers, and analyzing local data to identify areas where vaccination will have the greatest impact, given the varying risk levels across districts and seasons. Realistic delivery plans utilizing existing infrastructure, alongside thorough cost analyses and procurement options, are also crucial.
The Lassa fever Coalition’s Policy Research Working Group has engaged over 200 experts across West Africa to pinpoint the most pressing research questions that must be answered prior to vaccine distribution. The CEPI-funded Enable study is currently underway, tracking the prevalence of Lassa fever across the region – the largest study of its kind. Affected countries have also made strides in strengthening disease surveillance, improving laboratory systems, and establishing clinical trial networks.
Further efforts are needed to identify the data required to pinpoint high-risk groups and areas, develop effective delivery strategies, and assess financing needs. Regional bodies like WAHO should work to align regulatory processes and establish channels for rapid guidance once trial results become available. Technical agencies and partners can provide support for operational research and surveillance improvements that individual countries may lack the resources to undertake independently.
Building community trust is paramount to a successful vaccine rollout. Community organizations should commence raising awareness about Lassa fever and fostering confidence in the vaccine well before doses become available, particularly in communities where the disease is feared or stigmatized.
While some argue that it is premature to act given that vaccine candidates are still in trials and budgets are constrained, experts emphasize that the long timeline for vaccine development necessitates early action. Establishing regulatory systems, securing financing, and building community engagement structures are time-consuming processes that must begin now to ensure a rapid and effective response when a vaccine is licensed.
National policymakers should begin laying the groundwork to clarify rollout locations, financing mechanisms, and community engagement strategies. A Lassa fever vaccine represents a significant scientific advancement, but its impact will be limited unless countries are fully prepared to utilize it.
